StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report sent to investors on Sunday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
TTNP opened at $5.19 on Friday. The company’s 50-day simple moving average is $5.93 and its two-hundred day simple moving average is $6.39. Titan Pharmaceuticals has a 52-week low of $4.24 and a 52-week high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Recommended Stories
- Five stocks we like better than Titan Pharmaceuticals
- What is a buyback in stocks? A comprehensive guide for investors
- Should You Invest in Treasury Bills?
- How to Calculate Inflation Rate
- Analysts Think There’s Still Time to Get in on Edgewise, Up 332%
- Which Wall Street Analysts are the Most Accurate?
- 3 Stocks Raising Dividends 4X Higher Than Inflation
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
